Scinai Immunotherapeutics Ltd (SCNI) - Net Assets
Based on the latest financial reports, Scinai Immunotherapeutics Ltd (SCNI) has net assets worth $8.10 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($11.63 Million) and total liabilities ($3.52 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Scinai Immunotherapeutics Ltd tangible book value ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $8.10 Million |
| % of Total Assets | 69.7% |
| Annual Growth Rate | N/A |
| 5-Year Change | 725.15% |
| 10-Year Change | 21.87% |
| Growth Volatility | 229.46 |
Scinai Immunotherapeutics Ltd - Net Assets Trend (2000–2025)
This chart illustrates how Scinai Immunotherapeutics Ltd's net assets have evolved over time, based on quarterly financial data. See defensive interval ratio of Scinai Immunotherapeutics Ltd to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Scinai Immunotherapeutics Ltd (2000–2025)
The table below shows the annual net assets of Scinai Immunotherapeutics Ltd from 2000 to 2025. For live valuation and market cap data, see SCNI market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $8.10 Million | -18.78% |
| 2024-12-31 | $9.98 Million | +318.36% |
| 2023-12-31 | $-4.57 Million | -159.60% |
| 2022-12-31 | $-1.76 Million | -279.23% |
| 2021-12-31 | $982.00K | +121.62% |
| 2020-12-31 | $-4.54 Million | +75.89% |
| 2019-12-31 | $-18.84 Million | -125.68% |
| 2018-12-31 | $-8.35 Million | -151.63% |
| 2017-12-31 | $16.17 Million | +143.15% |
| 2016-12-31 | $6.65 Million | -22.77% |
| 2015-12-31 | $8.61 Million | +102.23% |
| 2014-12-31 | $4.26 Million | -38.46% |
| 2013-12-31 | $6.92 Million | +16.21% |
| 2012-12-31 | $5.95 Million | -11.33% |
| 2011-12-31 | $6.71 Million | -15.44% |
| 2010-12-31 | $7.94 Million | -5.92% |
| 2009-12-31 | $8.44 Million | +181.28% |
| 2008-12-31 | $3.00 Million | +190.49% |
| 2007-12-31 | $-3.31 Million | -290.08% |
| 2006-12-31 | $1.74 Million | -35.46% |
| 2005-12-31 | $2.70 Million | -34.18% |
| 2004-12-31 | $4.11 Million | +533.49% |
| 2003-12-31 | $648.00K | +620.00% |
| 2002-12-31 | $90.00K | +2350.00% |
| 2001-12-31 | $-4.00K | +83.33% |
| 2000-12-31 | $-24.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Scinai Immunotherapeutics Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 12584600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Comprehensive Income | $-1.74 Million | -21.47% |
| Other Components | $135.69 Million | 1674.55% |
| Total Equity | $8.10 Million | 100.00% |
Scinai Immunotherapeutics Ltd Competitors by Market Cap
The table below lists competitors of Scinai Immunotherapeutics Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Modiin Energy-Limited Partnership
TA:MDIN-L
|
$1.34 Million |
|
NamR SA
PA:ALNMR
|
$1.34 Million |
|
Eason Technology Limited
NYSE MKT:DXF
|
$1.34 Million |
|
ULTRA LITHIUM
F:QFB
|
$1.34 Million |
|
Silver Spruce Resources Inc
V:SSE
|
$1.33 Million |
|
LIQUID AVATAR TECHNO.INC.
F:4T5
|
$1.33 Million |
|
Univa Foods Limited
NSE:UNIVAFOODS
|
$1.33 Million |
|
Hydro Exploitations SA
PA:MLHYE
|
$1.33 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Scinai Immunotherapeutics Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 9,977,000 to 8,103,000, a change of -1,874,000 (-18.8%).
- Net loss of 8,307,000 reduced equity.
- New share issuances of 5,770,000 increased equity.
- Other factors increased equity by 663,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-8.31 Million | -102.52% |
| Share Issuances | $5.77 Million | +71.21% |
| Other Changes | $663.00K | +8.18% |
| Total Change | $- | -18.78% |
Book Value vs Market Value Analysis
This analysis compares Scinai Immunotherapeutics Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.10x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2008-12-31 | $470.40 | $0.34 | x |
| 2009-12-31 | $1103.69 | $0.34 | x |
| 2010-12-31 | $890.61 | $0.34 | x |
| 2011-12-31 | $695.95 | $0.34 | x |
| 2012-12-31 | $565.05 | $0.34 | x |
| 2013-12-31 | $577.06 | $0.34 | x |
| 2014-12-31 | $313.67 | $0.34 | x |
| 2015-12-31 | $326.33 | $0.34 | x |
| 2016-12-31 | $196.86 | $0.34 | x |
| 2017-12-31 | $321.66 | $0.34 | x |
| 2018-12-31 | $-127.72 | $0.34 | x |
| 2019-12-31 | $-230.68 | $0.34 | x |
| 2020-12-31 | $-40.98 | $0.34 | x |
| 2021-12-31 | $6.96 | $0.34 | x |
| 2022-12-31 | $-9.34 | $0.34 | x |
| 2023-12-31 | $-11.70 | $0.34 | x |
| 2024-12-31 | $12.37 | $0.34 | x |
| 2025-12-31 | $3.47 | $0.34 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Scinai Immunotherapeutics Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -102.52%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -633.64%
- • Asset Turnover: 0.11x
- • Equity Multiplier: 1.43x
- Recent ROE (-102.52%) is below the historical average (-64.78%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2004 | 25.65% | 18.05% | 1.13x | 1.25x | $642.50K |
| 2008 | -40.36% | 0.00% | 0.00x | 1.07x | $-1.51 Million |
| 2009 | -13.81% | 0.00% | 0.00x | 1.06x | $-2.01 Million |
| 2010 | -31.34% | 0.00% | 0.00x | 1.09x | $-3.28 Million |
| 2011 | -32.18% | 0.00% | 0.00x | 1.07x | $-2.83 Million |
| 2012 | -40.79% | 0.00% | 0.00x | 1.05x | $-3.02 Million |
| 2013 | -33.50% | 0.00% | 0.00x | 1.08x | $-3.01 Million |
| 2014 | -46.81% | 0.00% | 0.00x | 1.11x | $-2.42 Million |
| 2015 | -30.40% | 0.00% | 0.00x | 1.23x | $-3.48 Million |
| 2016 | -35.86% | 0.00% | 0.00x | 1.18x | $-3.05 Million |
| 2017 | -61.42% | 0.00% | 0.00x | 1.45x | $-11.55 Million |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-22.62 Million |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-29.74 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-931.88K |
| 2021 | -835.64% | 0.00% | 0.00x | 32.62x | $-8.30 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-5.62 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-6.04 Million |
| 2024 | 48.07% | 728.88% | 0.05x | 1.35x | $3.80 Million |
| 2025 | -102.52% | -633.64% | 0.11x | 1.43x | $-9.12 Million |
Industry Comparison
This section compares Scinai Immunotherapeutics Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $155,285,360
- Average return on equity (ROE) among peers: -101.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Scinai Immunotherapeutics Ltd (SCNI) | $8.10 Million | 25.65% | 0.43x | $1.33 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $83.17 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $-26.99 Million | 0.00% | 0.00x | $321.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $182.50 Million | -46.25% | 0.30x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $4.59 Million | -357.76% | 1.38x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $33.94 Million | -14.97% | 0.12x | $7.98 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $113.93 Million | -49.49% | 0.18x | $3.66 Billion |
About Scinai Immunotherapeutics Ltd
Scinai Immunotherapeutics Ltd., together with its subsidiaries, operates as a biopharmaceutical company in Israel and internationally. It engages in the research and development of IL-17 NanoAb, a VHH-based antibody platform for the treatment of immune-mediated and inflammatory diseases, including psoriasis; and PC111, a human monoclonal antibody for the treatment of pemphigus, Steven Johnson's s… Read more